FDA approves Constipation Drug

Updated at: Dec 27, 2012
FDA approves Constipation Drug

Infrequent bowel movements or constipation can advance to serious medical conditions if not reported on time. And because constipation is not something one openly talks about, it is left untreated. But, with this drug that the FDA has approved, co

Gunjan Rastogi
LatestWritten by: Gunjan RastogiPublished at: Sep 01, 2012

The US FDA approves Constipation Drug

Constipation troubling you for long? Here is a good news: the US Food and Drug Administration (FDA) has approved a constipation drug. Manufactured by Ironwood Pharmaceuticals, this drug can cure chronic constipation and bowel syndrome accompanied by constipation in adults.

Not recommended for patients aged 16 and below, this drug named linaclotide will be available under the brand name Linzess. The FDI said that this once-a-day pill will result in frequent bowel movements easing constipation and will also relieve abdominal pain caused by troublesome bowel syndrome. [Read: Remedies for Constipation]

The manufacturing company, Ironwood and its marketing partner, Forest Laboratories, have indicated the entry of the constipation pill in the market by the fourth quarter of this year.

This constipation drug will be most beneficial for those diagnosed with chronic idiopathic constipation, a condition in which standard treatment for persistent constipation fails. During the clinical studies, diarrhoea was the most common side-effect of this constipation pill.




All possible measures have been taken to ensure accuracy, reliability, timeliness and authenticity of the information; however Onlymyhealth.com does not take any liability for the same. Using any information provided by the website is solely at the viewers’ discretion. In case of any medical exigencies/ persistent health issues, we advise you to seek a qualified medical practitioner before putting to use any advice/tips given by our team or any third party in form of answers/comments on the above mentioned website.

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK